Related Experiment Video
Updated: Apr 5, 2026

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
Published on: June 18, 2013
Tumor-specific penetrating peptides-functionalized hyaluronic acid-d-α-tocopheryl succinate based nanoparticles for
De-Sheng Liang1, Hai-Tao Su1, Yu-Jie Liu1
1School of Pharmaceutical Sciences, Peking University, 38 Xueyuan Road, Haidian District, Beijing 100191, PR China; Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, 38 Xueyuan Road, Haidian District, Beijing 100191, PR China.
Abstract:
Poor site-specific delivery and incapable deep-penetration into tumor are the intrinsic limitations to successful chemotherapy. Here, the tumor-homing penetrating peptide tLyP-1-functionalized nanoparticles (tLPTS/HATS NPs), composed of two modularized amphiphilic conjugates of tLyP-1-PEG-TOS (tLPTS) and TOS-grafted hyaluronic acid (HATS), had been fabricated for tumor-targeted delivery of docetaxel (DTX). The prepared tLPTS/HATS NPs had about 110 nm in mean diameter, high drug encapsulation efficiency (93%), and sustained drug release behavior. In vitro studies demonstrated that the tLPTS/HATS NPs exhibited enhanced intracellular delivery and much better anti-invasion ability, cytotoxicity, and apoptosis against both invasive PC-3 and MDA-MB-231 cells as compared to the non-tLyP-1-functionalized HATS NPs. The remarkable penetrability and inhibitory effect on both PC-3 and MDA-MB-231 multicellular tumor spheroids were also identified for the tLPTS/HATS NPs. In vivo biodistribution imaging demonstrated the tLPTS/HATS NPs possessed much more lasting accumulation and extensive distribution throughout tumor regions than the HATS NPs. The higher in vivo therapeutic efficacy with lower systemic toxicity of the tLPTS/HATS NPs was also verified by the PC-3 xenograft model in athymic nude mice. These results suggested that the designed novel tLPTS/HATS NPs were endowed with tumor recognition, internalization, penetration, and anti-invasion, and thus might be a promising anticancer drug delivery vehicle for targeted cancer therapy.
Insights
Novel nanoparticles functionalized with tumor-homing peptides improve docetaxel delivery, enhancing anti-cancer effects and reducing toxicity. These targeted nanoparticles show promise for effective cancer therapy.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Drug Delivery
Background:
- Chemotherapy faces challenges with poor tumor-specific delivery and deep penetration.
- Effective cancer treatment requires overcoming these limitations for improved therapeutic outcomes.
Purpose of the Study:
- To develop and evaluate tumor-homing peptide tLyP-1-functionalized nanoparticles (tLPTS/HATS NPs) for targeted docetaxel (DTX) delivery.
- To assess the in vitro and in vivo performance of these novel nanoparticles for cancer therapy.
Main Methods:
- Fabrication of tLPTS/HATS NPs using modular amphiphilic conjugates.
- Characterization of NP size, drug encapsulation efficiency, and release kinetics.
- In vitro evaluation of cellular uptake, anti-invasion, cytotoxicity, and apoptosis.
- In vivo biodistribution imaging and therapeutic efficacy studies in a PC-3 xenograft model.
Main Results:
- tLPTS/HATS NPs demonstrated optimal size (~110 nm), high encapsulation (93%), and sustained release.
- Enhanced in vitro cellular delivery, anti-invasion, cytotoxicity, and apoptosis in cancer cells.
- Superior tumor spheroid penetration and growth inhibition.
- Increased tumor accumulation and distribution in vivo with reduced systemic toxicity.
Conclusions:
- tLPTS/HATS NPs exhibit tumor recognition, internalization, penetration, and anti-invasion capabilities.
- These nanoparticles represent a promising drug delivery vehicle for targeted cancer therapy.
- The developed system offers potential for enhanced therapeutic efficacy and reduced side effects.
More Related Videos
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
09:02Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Related Concept Videos
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Tumor Immunotherapy